MONTGOMERY, Texas--(BUSINESS WIRE)--AngioSoma, Inc. (OTCQB: SOAN) is in final negotiations with Dr. Jackie R. See, M.D., F.A.C.C. to join its Scientific Advisory Board. Dr. See was instrumental in the original development of liposomal PGE-1 and is involved in new, and still experimental, uses of PGE-1 and stem cell treatment for the acute stages of peripheral artery disease (‘PAD’). This opens new and important therapeutic pathways to future Liprostin™ treatments of not only PAD but a wide range of vascular and diabetes-related diseases. Dr. See is a Board Certified Internist, a Fellow of the American College of Cardiology, and pioneer of the specialty of Interventional Cardiology (further information on our website at http://angiosoma.com).
